Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 307

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

Open access
Faneyte, I F, Schrama, J G, Peterse, J L, Remijnse, P L, Rodenhuis, S, van de Vijver, M J·2003·British Journal of Cancer

Abstract

The aim of this study was to provide a better insight into breast cancer response to chemotherapy. Chemotherapy improves outcome in breast cancer patients. The effect of cytotoxic treatment cannot be predicted for individual patients. Therefore, the identification of tumour characteristics associated with tumour response and outcome is of great clinical interest. We studied 97 patients, who received anthracycline-based neoadjuvant chemotherapy. Tumour samples were taken prior to and after chemotherapy. We quantified the response to chemotherapy clinically and pathologically and determined histological and molecular tumour characteristics. We assessed changes in the expression of Bcl-2, ER, P53 HER2 and Ki-67. Association with response and outcome was tested for all parameters. The experimental results showed 15 clinical (17%) and three (3%) pathological complete remissions. There were 18 (20%) clinical vs 29 (33%) pathological nonresponders. The expression of most markers was similar before and after chemotherapy. Only Ki-67 was significantly decreased after chemotherapy. Factors correlated with response were: large tumour size, ER negativity, high Ki-67 count and positive P53 status. Tumour response and marker expression did not predict disease-free or overall survival. In conclusion, clinical and pathological response assessments are poorly associated. Proliferation decreases significantly after chemotherapy. ER negativity and a high proliferation index are associated with better response. HER2 status does not predict response, and outcome is not related to tumour response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6600749

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 307

Metadata

Authors
Faneyte, I. F., Schrama, J. G., Peterse, J. L., Remijnse, P. L., Rodenhuis, S., & van de Vijver, M. J.
Venue
British Journal of Cancer
Published
2003-02
Volume
88
Issue
3
Pages
406-412
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2083803850
Cited by
307
References
18
FWCI
7.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. https://app.cochat.ai/papers/10.1038/sj.bjc.6600749
The paper
Faneyte, I. F., Schrama, J. G., Peterse, J. L., Remijnse, P. L., Rodenhuis, S., & van de Vijver, M. J. (2003). Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6600749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.